HEAT BIOLOGICS INC (HTBX) Stock Price, Forecast & Analysis
USA - NYSEARCA:HTBX - US42237K4094 - Common Stock
HTBX Key Statistics, Chart & Performance
The current stock price of HTBX is 2.38 null. In the past month the price decreased by -22.98%. In the past year, price decreased by -61.92%.
HTBX Latest News, Press Relases and Analysis
HTBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.45 | 408.15B | ||
| AMGN | AMGEN INC | 15.57 | 183.27B | ||
| GILD | GILEAD SCIENCES INC | 15.48 | 157.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.19 | 107.65B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.64 | 74.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 905.49 | 60.53B | ||
| INSM | INSMED INC | N/A | 42.73B | ||
| NTRA | NATERA INC | N/A | 29.87B | ||
| BIIB | BIOGEN INC | 9.97 | 24.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 21.55B | ||
| INCY | INCYTE CORP | 15.84 | 19.86B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.3 | 13.80B |
Related stock screener links
About HTBX
Company Profile
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.
Company Info
HEAT BIOLOGICS INC
627 Davis Drive, Suite 400
Morrisville NORTH CAROLINA 27560 US
CEO: Jeffrey Wolf
Employees: 49
Phone: 19192407133.0
HEAT BIOLOGICS INC / HTBX FAQ
What does HEAT BIOLOGICS INC do?
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.
What is the stock price of HEAT BIOLOGICS INC today?
The current stock price of HTBX is 2.38 null. The price increased by 0.42% in the last trading session.
What is the dividend status of HEAT BIOLOGICS INC?
HTBX does not pay a dividend.
How is the ChartMill rating for HEAT BIOLOGICS INC?
HTBX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is HTBX stock listed?
HTBX stock is listed on the NYSE Arca exchange.
How is the valuation of HEAT BIOLOGICS INC (HTBX) based on its PE ratio?
HEAT BIOLOGICS INC (HTBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).
How many employees does HEAT BIOLOGICS INC have?
HEAT BIOLOGICS INC (HTBX) currently has 49 employees.
HTBX Technical Analysis
HTBX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to HTBX. The financial health of HTBX is average, but there are quite some concerns on its profitability.
HTBX Financial Highlights
Over the last trailing twelve months HTBX reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 9.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1658.78% | ||
| ROA | -28.99% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
HTBX Forecast & Estimates
10 analysts have analysed HTBX and the average price target is 11.6 null. This implies a price increase of 387.5% is expected in the next year compared to the current price of 2.38.
For the next year, analysts expect an EPS growth of -23.7% and a revenue growth 128.57% for HTBX